Home › Fabry Disease › Georgia › Atlanta
Fabry Disease clinical trials in Atlanta, GA
6 studies for Fabry Disease are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
RecruitingPhase 1/2
- Emory University School of Medicine, Atlanta
A Study of Patients With Fabry Disease (US Specific)
RecruitingObservational study
- Emory Genetics, Atlanta
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RecruitingPhase 3
- Emory Genetics, Atlanta
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RecruitingPhase 2/3
- Emory Genetics Clinical Trials Center, Atlanta
Fabry Disease Registry & Pregnancy Sub-registry
RecruitingObservational study
- Emory University School of Medicine- Human Genetics- Site Number : 840060, Decatur · 6 mi away
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
RecruitingObservational study
- Emory University School of Medicine, Atlanta
Fabry Disease trials in other cities
- Arlington, VA6 studies
- Birmingham, AL4 studies
- Minneapolis, MN4 studies
- Cincinnati, OH4 studies
- Pittsburgh, PA4 studies
- New York City, NY3 studies
- Salt Lake City, UT3 studies
- Cedar Rapids, IA3 studies
- Chicago, IL3 studies
Other studies in Atlanta
- Cancer (all types)49 studies
- Non-Small Cell Lung Cancer47 studies
- Breast Cancer41 studies
- Multiple Myeloma41 studies
- Prostate Cancer33 studies
- Acute Myeloid Leukemia30 studies
- Ovarian Cancer29 studies
- Lung Cancer29 studies
- Colorectal Cancer29 studies
- Metastatic Cancer28 studies
- Heart Failure25 studies
- Major Depressive Disorder25 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.